Assessment of the Expression of GLUT1 in Renal Cell Carcinoma and its Various Subtypes

Mitra Abdolahi; Mostafa Alam; Arash Ghaffarpasand; Farzad Nouri; Ashkan Badkoobeh; Mohsen Golkar; Kamyar Abassi; Peyman Torbati

doi:10.3889/oamjms.2022.10904

Authors

Mitra Abdolahi Department of Pathology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Mostafa Alam Department of Oral and Maxillofacial Surgery, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Arash Ghaffarpasand Department of Oral and Maxillofacial Surgery, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Farzad Nouri Department of Oral and Maxillofacial Surgery, School of Dentistry, Zahedan University of Medical Sciences, Zahedan, Iran
Ashkan Badkoobeh Department of Oral and Maxillofacial Surgery, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Mohsen Golkar Department of Oral and Maxillofacial Surgery, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Kamyar Abassi Department of Prosthodontics, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Peyman Torbati Department of Pathology, School of Medicine and Labafinezhad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

DOI:

https://doi.org/10.3889/oamjms.2022.10904

Keywords:

Renal cell carcinoma, Glucose transporter 1, RCC immunohistochemistry

Abstract

BACKGROUND: Renal cell carcinoma is one of the most common tumors of the kidney. Glucose transporters, transport glucose, and increased expression of these transporters have been reported in various tumor types. Glucose transporter 1 (GLUT1), the best-known glucose transporter, has an important role at several stages in cancer progression. The overexpression of GLUT1 in the tumor cells indicates an increased proliferation and invasive behavior of the tumor.

AIM: This study aims to investigate the expression of GLUT1 in renal cell carcinoma and its subtypes.

METHODS: This study is a descriptive cross-sectional study that was performed on patients with renal cell carcinoma. Seventy reports of formalin fixed; paraffin-embedded blocks of renal cell carcinoma were selected from pathology archives. The samples included: clear cell type renal cell carcinoma, RCC clear cell type with sarcomatoid feature, papillary renal cell carcinoma, and chromophobe renal cell carcinoma.

RESULTS: In this study, 50 male and 20 female samples (71.4% and 28.6%) with the mean age of 57.9 ± 13.1 years were studied. Forty-three samples (61.4%) were positive for GLUT1 and 27 (38.9%) were negative for it. For the GLUT1 expression being positive or negative between the two groups, was not significantly affected by the age, sex, and the grade of the tumor, </AQ17>while the difference between the two groups was statistically significant in terms of stage and type of tumor (p < 0/001, p = 0.039).

CONCLUSION: Renal cell carcinoma of ccRCC type is associated with increased GLUT1 expression. Therefore, the GLUT1 immunohistochemistry marker can be a useful marker for diagnosis of RCC, specifically ccRCC type.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A, et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med. 2011;3(94):94ra70. https://doi.org/10.1126/scitranslmed.3002394 PMid:21813754

Aparicio LM, Villaamil VM, Calvo MB, Rubira LV, Rois JM, Valladares-Ayerbes M, et al. Glucose transporter expression and the potential role of fructose in renal cell carcinoma: A correlation with pathological parameters. Mol Med Rep. 2010;3(4):575-80. https://doi.org/10.3892/mmr_00000300 PMid:21472282

Cantuaria G, Fagotti A, Ferrandina G, Magalhaes A, Nadji M, Angioli R, et al. GLUT‐1 expression in ovarian carcinoma: Association with survival and response to chemotherapy. 2001;92(5):1144-50. https://doi.org/10.1002/1097-0142(20010901)92:5<1144:aid-cncr1432>3.0.co;2-t PMid:11571727

Mosaddad SA, Beigi K, Doroodizadeh T, Haghnegahdar M, Golfeshan F,Ranjbar R, et al. Therapeutic applications of herbal/ synthetic/bio-drug in oral cancer: An update. Eur J Pharmacol. 2021;890:173657. https://doi.org/10.1016/j.ejphar.2020.173657 PMid:33096111

Hajmohammadi E, Molaei T, Mowlaei SH, Alam M, Abbasi K, Khayatan D, et al. Sonodynamic therapy and common head and neck cancers: In vitro and in vivo studies. Eur Rev Med Pharmacol Sci. 2021;25(16):5113-21. https://doi.org/10.26355/eurrev_202108_26522 PMid:34486685

Hajmohammadi E, Hajmohammadi E, Ghahremanie S, Alam M, Abbasi K, Mohamadian F, Khayatan D, et al. Biomarkers and common oral cancers: Clinical trial studies. JBUON. 2021;26(6):2227-37.

Tahmasebi E, Alikhani M, Yazdanian A, Yazdanian M, Tebyanian H, Seifalian A. The current markers of cancer stem cell in oral cancers. Life Sci. 2020;249:117483. https://doi.org/10.1016/j.lfs.2020.117483 PMid:32135187

Ozcan A, Shen SS, Zhai QJ, Truong LD. Expression of GLUT1 in primary renal tumors: Morphologic and biologic implications. Am J Clin Pathol. 2007;128(2):245-54. https://doi.org/10.1309/HV6NJVRQKK4QHM9F PMid:17638658

Hussain A, Tebyaniyan H, Khayatan D. The role of epigenetic in dental and oral regenerative medicine by different types of dental stem cells: A comprehensive overview. Stem Cells Int. 2022;2022:5304860. https://doi.org/10.1155/2022/5304860 PMid:35721599

Soudi A, Yazdanian M, Ranjbar R, Tebyanian H, Yazdanian A, Tahmasebi E, et al. Role and application of stem cells in dental regeneration: A comprehensive overview. EXCLI J. 2021;20:454-89. https://doi.org/10.17179/excli2021-3335 PMid:33746673

Zolfaghar M, Amoozegar MA, Khajeh K, Babavalian H, Tebyanian H. Isolation and screening of extracellular anticancer enzymes from halophilic and halotolerant bacteria from different saline environments in Iran. Mol Biol. Rep. 2019;46(3):3275-86. https://doi.org/10.1007/s11033-019-04787-7 PMid:30993582

Kafshgari HS, Yazdanian M, Ranjbar R, Tahmasebi E, Mirsaeed SR, Tebyanian H, et al. The effect of Citrullus colocynthis extracts on Streptococcus mutans, Candida albicans, normal gingival fibroblast and breast cancer cells. J Biol Res. 2019;92(1):8201. https://doi.org/10.4081/jbr.2019.8201

Rezaeeyan Z, Safarpour A, Amoozegar MA, Babavalian H, Tebyanian H, Shakeri F. High carotenoid production by a halotolerant bacterium, Kocuria sp. strain QWT-12 and anticancer activity of its carotenoid. EXCLI J. 2017;16:840-51. https://doi.org/10.17179/excli2017-218 PMid:28827999

Ito S, Fukusato T, Nemoto T, Sekihara H, Seyama Y, Kubota S. Coexpression of glucose transporter 1 and matrix metalloproteinase-2 in human cancers. J Natl Cancer Inst. 2002;94(14):1080-91. https://doi.org/10.1093/jnci/94.14.1080 PMid:12122099

Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, et al. Expression of glucose transporter‐1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001;92(3):634-41. https://doi.org/10.1002/1097-0142(20010801)92:3<634:aid-cncr1364>3.0.co;2-x PMid:11505409

Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202(3):654-62. https://doi.org/10.1002/jcp.20166 PMid:15389572

Kresnik E, Gallowitsch HJ, Mikosch P, Stettner H, Igerc I, Gomez I, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. Surgery. 2003;133(3):294-9. https://doi.org/10.1067/msy.2003.71 PMid:12660642

Manolescu AR, Witkowska k, Kinnaird A, Cessford T, Cheeseman C. Facilitated hexose transporters: New perspectives on form and function. Physiology (Bethesda). 2007;22(4):234-40. https://doi.org/10.1152/physiol.00011.2007 PMid:17699876

Mueckler M. Facilitative glucose transporters. Eur J Biochem. 1994;219(3):713-25. https://doi.org/10.1111/j.1432-1033.1994.tb18550.x PMid:8112322

Schürmann A. Insight into the “odd” hexose transporters GLUT3, GLUT5, and GLUT7. Am J Physiol Endocrinol Metab. 2008;295(2):E225-6. https://doi.org/10.1152/ajpendo.90406.2008 PMid:18460594

Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, et al. c-Myc transactivation of LDH-A: Implications for tumor metabolism and growth. Proc Natl Acad Sci U S A. 1997;94(13):6658-63. https://doi.org/10.1073/pnas.94.13.6658 PMid:9192621

Hediger MA, Coady MJ, Ikeda TS, Wright EM. Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature. 1987;330(6146):379-81. https://doi.org/10.1038/330379a0 PMid:2446136

Carvalho KC, Cunha IW, Rocha RM, Ayala FR, Cajaíba MM, Soares FA, et al. GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics (Sao Paulo). 2011;66(6):965-72. https://doi.org/10.1590/S1807-59322011000600008 PMid:21808860

Bell GI, Kayano T, Buse JB, Burant CF, Takeda J, Lin D, et al. Molecular biology of mammalian glucose transporters. Diabetes Care. 1990;13(3):198-208. https://doi.org/10.2337/diacare.13.3.198 PMid:2407475

Bellocco R, Pasquali E, Rota M, Bagnardi V, Tramacere I, Scotti L. et al. Alcohol drinking and risk of renal cell carcinoma: Results of a meta-analysis. Ann Oncol. 2012;23(9):2235-44. https://doi.org/10.1093/annonc/mds022 PMid:22398178

Nagase Y, Takata K, Moriyama N, Aso Y, Murakami T, Hirano H. Immunohistochemical localization of glucose transporters in human renal cell carcinoma. J Urol. 1995;153(3 Pt 1):798-801. https://doi.org/10.1016/S0022-5347(01)67725-5 PMid:7861542

Miyakita H, Onda H, Usui Y, Kinoshita H, Kawamura N, Yasuda S, et al. Significance of 18F‐fluorodeoxyglucose positron emission tomography (FDG‐PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT‐1) expression in the cancer. Int J Urol. 2002;9(1):15-8. https://doi.org/10.1046/j.1442-2042.2002.00416.x PMid:11972644

Suganuma N, Segade F, Matsuzu K, Bowden DW. Differential expression of facilitative glucose transporters in normal and tumour kidney tissues. BJU Int. 2007;99(5):1143-9. https://doi.org/10.1111/j.1464-410X.2007.06765.x PMid:17437443

Ambrosetti D, Dufies M, Dadone B, Durand M, Borchiellini D, Amiel J, et al. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma. PLoS One. 2018;13(2):e0193477. https://doi.org/10.1371/journal.pone.0193477 PMid:29481555